

FORM PCT/US (REV. 1-98) 03/21/01		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTORNEY'S DOCKET NUMBER 12964.22	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 09/787860	
INTERNATIONAL APPLICATION NO. PCT/EP99/07054	INTERNATIONAL FILING DATE 22 SEPTEMBER 1999	PRIORITY DATE CLAIMED 22 SEPTEMBER 1998	
TITLE OF INVENTION USE OF GREGANOPHOSPHOROUS COMPOUNDS FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS FOR THE THERAPEUTIC AND PROPHYLACTIC TREATMENT OF INFECTIONS OR AS A FUNGICIDE, BACTERICIDE OR HERBICIDE IN PLANTS			
APPLICANT(S) FOR DO/EO/US JOMAA, Hassan			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired d. <input type="checkbox"/> have not been made and will not be made 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). UNEXECUTED 10. <input type="checkbox"/> A translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).			
Items 11. to 16. below concern document(s) or information included:			
11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> A substitute specification. 15. <input type="checkbox"/> A change of power of attorney and/or address letter. 16. <input checked="" type="checkbox"/> Other items or information: Post Card, Express Mail Certificate, International Search Report in German, and Preliminary Examination Report in German			

d846569.1

U.S. APPLICATION NO. 09/787860		INTERNATIONAL APPLICATION NO. PCT/EP99/07054		ATTORNEY'S DOCKET NUMBER 12964.22					
17 <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$970.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$760.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$670.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$96.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				CALCULATIONS PTO USE ONLY <table style="width: 100%;"> <tr> <td style="width: 50%;">\$ 860.00</td> <td style="width: 50%;"></td> </tr> <tr> <td>\$ 130.00</td> <td></td> </tr> </table>		\$ 860.00		\$ 130.00	
\$ 860.00									
\$ 130.00									
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(c)).				<table style="width: 100%;"> <tr> <td style="width: 50%;"></td> <td style="width: 50%;"></td> </tr> <tr> <td></td> <td>\$ 130.00</td> </tr> </table>					\$ 130.00
	\$ 130.00								
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$					
Total claims	27 - 20 =	7	x \$18	\$ 126.00					
Independent claims	1 - 3 =	0	x \$80	\$ 0.00					
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ 270					
				\$ 270.00					
TOTAL OF ABOVE CALCULATIONS =				\$ 1386.00					
Reduction of 1/2 for filing by small entity, if applicable A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28)				+ \$					
SUBTOTAL =				\$ 1386.00					
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				+ \$ 0.00					
TOTAL NATIONAL FEE =				\$ 1386.00					
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				+ \$					
TOTAL FEES ENCLOSED =				\$ 1386.00					
				Amount to be refunded: \$					
				charged: \$					

- a. ☒ A check in the amount of \$ 1386.00 to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees.
 A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any
 overpayment to Deposit Account No. 08-1394. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO

Warren B. Kice
 Haynes and Boone, L. L. P.
 901 Main Street, Suite 3100
 Dallas, Texas 75202
 Phone: [214] 651-5634
 Fax: [214] 651-5940

SIGNATURE

Warren B. Kice

NAME

22,732

REGISTRATION NUMBER

ROSPOT/10

18 JUN 2002

007507860.061802

#4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	§
Hassan Jomaa	§ Attorney Docket No.: 12964.22
Serial No.: United States National Phase	§
of PCT/EP99/07054	§ I. A. Filing Date: 22 September 1999
Filed: Herewith	§ Priority Date: 22 September 1998
For: USE OF ORGANOPHOSPHORUS	§
COMPOUNDS FOR THE PRODUCTION	§
OF PHARMACEUTICAL PREPARATIONS	§
FOR THE THERAPEUTIC AND	§
PROPHYLACTIC TREATMENT OF	§
INFECTIONS OR AS A FUNGICIDE,	§
BACTERICIDE OR HERBICIDE IN	§
PLANTS (as amended)	§

Attention: DO/EO/US
Commissioner For Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Dear Sir:

Prior to the initial examination of the above-identified application, please amend the application as follows:

IN THE TITLE:

(Amended)

Use of Organophosphorus compounds for the Production of Pharmaceutical Preparations for the Therapeutic and Prophylactic Treatment of Infections or as a Fungicide, Bactericide or Herbicide in Plants

IN THE CLAIMS:

6. (once amended) Use according to one of claims 2, 3, and 5, characterised in that

R₂ is an acyl residue and A an alkylene residue, wherein R₂ is preferably formed by formyl or acetyl and A preferably by propylene, propenylene and hydroxypropylene.

7. (once amended) Use according to one of claims 1, 2, 3, and 5 for the production of pharmaceutical preparations for the treatment of infections caused by bacteria, viruses, fungi or uni- or multicellular parasites.
11. (once amended) Use according to one of claims 1, 2, 3, 5, 8, 9, and 10 characterised in that the pharmaceutical preparation comprises an effective content of at least one organophosphorus compound and a pharmaceutically acceptable excipient.

REMARKS

Claims 1-14 remain in the application. Claims 6, 7, and 11 have been amended. The filing fee has been calculated according to the above-amendments.

Should the Examiner have any questions or comments regarding the amendments, the Examiner is invited to telephone the undersigned at the number listed below.

Respectfully submitted,



Warren B. Kice
Registration No. 22,732

Dated: 3/21/01
HAYNES AND BOONE, L.L.P.
901 Main Street, Suite 3100
Dallas, Texas 75202-3789
Telephone: 214/651-5634
Fax: 214/651-5940
Docket Number: 12964.22
D-880393.1

EXPRESS MAIL NO.: EL418590666US

DATE OF DEPOSIT: March 21, 2001

This paper and fee are being deposited with the U.S. Postal Service Express Mail Post Office to Addressee service under 37 CFR §1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231

Lidia Epps-Hilliard
Name of person mailing paper and fee

Lidia Epps-Hilliard
Signature of person mailing paper and fee

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	§
Hassan Jomaa	§ Attorney Docket No.: 12964.22
Serial No.: United States National Phase	§ I. A. Filing Date: 22 September 1999
of PCT/EP99/07054	§
Filed: Herewith	§ Priority Date: 22 September 1998
For: USE OF ORGANOPHOSPHORUS	§
COMPOUNDS FOR THE PRODUCTION	§
OF PHARMACEUTICAL PREPARATIONS	§
FOR THE THERAPEUTIC AND	§
PROPHYLACTIC TREATMENT OF	§
INFECTIONS OR AS A FUNGICIDE,	§
BACTERICIDE OR HERBICIDE IN	§
PLANTS (as amended)	§

Attention: DO/EO/US
 Commissioner For Patents
 Washington, D.C. 20231

REDLINE VERSION FOR PRELIMINARY AMENDMENTIn the Title:

(amended)

Use of Organophosphorus Compounds for the Production of Pharmaceutical Preparations
 [Producing Medicaments] for the Therapeutic and Prophylactic Treatment of Infections or as a
 Fungicide, Bactericide or Herbicide [for] in Plants

In the Claims

6. (once amended) Use according to one of claims [2 to 5] 2, 3, and 5,
 characterised in that
 R_2 is an acyl residue and A an alkylene residue, wherein R_2 is preferably formed by
 formyl or acetyl and A preferably by propylene, propenylene and hydroxypropylene.
7. (once amended) Use according to one of [the preceding] claims 1, 2, 3, and 5 for the
 production of pharmaceutical preparations for the treatment of infections caused by
 bacteria, viruses, fungi or uni- or multicellular parasites.

11. (once amended) Use according to one of claims [1 to 10] 1, 2, 3, 5, 8, 9, and 10 characterised in that the pharmaceutical preparation comprises an effective content of at least one organophosphorus compound and a pharmaceutically acceptable excipient.

JC10 Rec'd PCT/PTO 2 1 MAR 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:
Hassan Jomaa

Serial No.: United States National Phase
of PCT/EP99/07054

Filed: Herewith

For: USE OF ORGANOPHOSPHORUS
COMPOUNDS FOR THE PRODUCTION
OF PHARMACEUTICAL PREPARATIONS
FOR THE THERAPEUTIC AND
PROPHYLACTIC TREATMENT OF
INFECTIONS OR AS A FUNGICIDE,
BACTERICIDE OR HERBICIDE IN
PLANTS (as amended)

§
§ Attorney Docket No.: 12964.22
§
§ I. A. Filing Date: 22 September 1999
§
§ Priority Date: 22 September 1998
§
§
§
§
§
§
§
§
§
§

Attention: DO/EO/US
Commissioner For Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Dear Sir:

Prior to the initial examination of the above-identified application, please amend the application as follows:

IN THE TITLE:

(Amended)

Use of Organophosphorus compounds for the Production of Pharmaceutical Preparations for the Therapeutic and Prophylactic Treatment of Infections or as a Fungicide, Bactericide or Herbicide in Plants

IN THE CLAIMS:

6. (once amended) Use according to one of claims 2, 3, and 5, characterised in that
- R₂ is an acyl residue and A an alkylene residue, wherein R₂ is preferably formed by formyl or acetyl and A preferably by propylene, propenylene and hydroxypropylene.

7. (once amended) Use according to one of claims 1, 2, 3, and 5 for the production of pharmaceutical preparations for the treatment of infections caused by bacteria, viruses, fungi or uni- or multicellular parasites.
11. (once amended) Use according to one of claims 1, 2, 3, 5, 8, 9, and 10 characterised in that the pharmaceutical preparation comprises an effective content of at least one organophosphorus compound and a pharmaceutically acceptable excipient.

REMARKS

Claims 1-14 remain in the application. Claims 6, 7, and 11 have been amended. The filing fee has been calculated according to the above-amendments.

Should the Examiner have any questions or comments regarding the amendments, the Examiner is invited to telephone the undersigned at the number listed below.

Respectfully submitted,



Warren B. Kice
Registration No. 22,732

Dated: 3/21/01
HAYNES AND BOONE, L.L.P.
901 Main Street, Suite 3100
Dallas, Texas 75202-3789
Telephone: 214/651-5634
Fax: 214/651-5940
Docket Number: 12964.22
D-880393.1

EXPRESS MAIL NO.: EL418590666US

DATE OF DEPOSIT: April 21, 2001

This paper and fee are being deposited with the U.S. Postal Service Express Mail Post Office to Addressee service under 37 CFR §1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231

Lidia Epps-Hilliard
Name of person mailing paper and fee

[Signature]
Signature of person mailing paper and fee

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	§
Hassan Jomaa	§ Attorney Docket No.: 12964.22
Serial No.: United States National Phase	§
of PCT/EP99/07054	§ I. A. Filing Date: 22 September 1999
Filed: Herewith	§
	§ Priority Date: 22 September 1998
For: USE OF ORGANOPHOSPHORUS	§
COMPOUNDS FOR THE PRODUCTION	§
OF PHARMACEUTICAL PREPARATIONS	§
FOR THE THERAPEUTIC AND	§
PROPHYLACTIC TREATMENT OF	§
INFECTIONS OR AS A FUNGICIDE,	§
BACTERICIDE OR HERBICIDE IN	§
PLANTS (as amended)	§

Attention: DO/EO/US
Commissioner For Patents
Washington, D.C. 20231

REDLINE VERSION FOR PRELIMINARY AMENDMENTIn the Title:

(amended)

Use of Organophosphorus Compounds for the Production of Pharmaceutical Preparations
[Producing Medicaments] for the Therapeutic and Prophylactic Treatment of Infections or as a
Fungicide, Bactericide or Herbicide [for] in Plants

In the Claims

6. (once amended) Use according to one of claims [2 to 5] 2, 3, and 5,
characterised in that
R₂ is an acyl residue and A an alkylene residue, wherein R₂ is preferably formed by
formyl or acetyl and A preferably by propylene, propenylene and hydroxypropylene.
7. (once amended) Use according to one of [the preceding] claims 1, 2, 3, and 5 for the
production of pharmaceutical preparations for the treatment of infections caused by
bacteria, viruses, fungi or uni- or multicellular parasites.

11. (once amended) Use according to one of claims [1 to 10] 1, 2, 3, 5, 8, 9, and 10 characterised in that the pharmaceutical preparation comprises an effective content of at least one organophosphorus compound and a pharmaceutically acceptable excipient.

Use of organophosphorus compounds for the production of pharmaceutical preparations for the therapeutic and prophylactic treatment of infections or as a fungicide, bactericide or herbicide in plants


5 This invention relates to the use of organophosphorus compounds and the salts, esters and amides thereof for the production of pharmaceutical preparations for the therapeutic and prophylactic treatment of infections in humans and animals caused by viruses, bacteria, fungi and parasites, and to the use thereof as a fungicide, bactericide and herbicide in plants. According to the invention, the organophosphorus compounds
10 comprise phosphinoyl derivatives and phosphinic acid derivatives.

In order to widen the range of options for treating humans and animals and for protecting plants, there is an urgent requirement to provide agents which are not only highly active but, unlike other pharmaceutical preparations or phytosanitary agents,
15 also exhibit reduced side-effects and thus constitute a reduced risk to human health.

The object of the present invention is accordingly to provide a substance which is usable in infections by viruses, bacteria, fungi and parasites in humans and animals and as a fungicide, bactericide and herbicide in plants and which meets the above-
20 stated requirements.

This object is utterly surprisingly achieved by the group of substances defined in claim 1. This group of substances exhibits both an antiinfective action against viruses, certain bacteria, fungi, uni- and multicellular parasites and a fungicidal, bactericidal
25 and herbicidal action in plants.

The organophosphorus compounds used according to the invention are of the general formula (I):



in which R₁ and R₂ are identical or different and are selected from the group consisting of hydrogen, substituted and unsubstituted alkyl, substituted and unsubstituted hydroxyalkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted aryl, substituted and unsubstituted acyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted aralkyl, substituted and unsubstituted heterocyclic residue, halogen, OX₁ and OX₂, wherein X₁ and X₂ may be identical or different and are selected from the group consisting of hydrogen, substituted and unsubstituted alkyl, substituted and unsubstituted hydroxyalkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted aryl, substituted and unsubstituted acyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted aralkyl, substituted and unsubstituted heterocyclic residue.

A is selected from the group consisting of an alkylene residue, an alkenyl residue and a hydroxyalkylene residue.

R₃ is selected from the group consisting of hydrogen, substituted and unsubstituted alkyl, substituted and unsubstituted hydroxyalkyl, substituted and unsubstituted aryl, substituted and unsubstituted acyl, substituted and unsubstituted aralkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclic residue, halogen,

R₄ is selected from the group consisting of hydrogen, substituted and unsubstituted alkyl, substituted and unsubstituted hydroxyalkyl, substituted and unsubstituted aryl, substituted and unsubstituted acyl, substituted and unsubstituted aralkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclic residue, halogen, OX₄,

wherein X₄ is selected from the group consisting of hydrogen, substituted and unsubstituted alkyl, substituted and unsubstituted hydroxyalkyl, substituted and

5

10



15

20

25

Special features of the above definitions and suitable examples thereof are stated below:

- "Acyl" is a substituent which originates from an acid, such as from an organic carboxylic acid, carbonic acid, carbamic acid or the thioacid or imidic acid corresponding to the individual above-stated acids, or from an organic sulfonic acid, wherein these acids may in each case comprise aliphatic, aromatic and/or heterocyclic groups in the molecule, as well as carbamoyl or carbamimidoyl.

Suitable examples of these acyl groups are stated below.

- Aliphatic acyl groups are deemed to comprise acyl residues originating from an aliphatic acid, such groups including the following:
- alkanoyl (for example formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl *etc.*);
 - alkenoyl (for example acryloyl, methacryloyl, crotonoyl *etc.*);
 - alkylthioalkanoyl (for example methylthioacetyl, ethylthioacetyl *etc.*);
 - alkanesulfonyl (for example mesyl, ethanesulfonyl, propanesulfonyl *etc.*);
 - alkoxycarbonyl (for example methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl *etc.*);
 - alkylcarbamoyl (for example methylcarbamoyl *etc.*);
 - (N-alkyl)thiocarbamoyl (for example (N-methyl)thiocarbamoyl *etc.*);
 - alkylcarbamimidoyl (for example methylcarbamimidoyl *etc.*);
 - oxalo;
 - alkoxalyl (for example methoxalyl, ethoxalyl, propoxalyl *etc.*).
- In the above examples of aliphatic acyl groups, the aliphatic hydrocarbon moiety, in particular the alkyl group or alkane residue, may optionally comprise one or more suitable substituents, such as amino, halogen (for example fluorine, chlorine, bromine *etc.*), hydroxy, hydroxyimino, carboxy, alkoxy (for example methoxy, ethoxy, propoxy *etc.*), alkoxycarbonyl, acylamino (for example benzyloxycarbonylamino *etc.*), acyloxy (for example acetoxy, benzyloxy *etc.*) and the like; preferred aliphatic acyl residues having such substituents which may be mentioned are alkanoyls

substituted, for example, with amino, carboxy, amino and carboxy, halogen, acylamino or the like.

Aromatic acyl residues are deemed to comprise those acyl residue which originate from an acid with a substituted or unsubstituted aryl group, wherein the aryl group may comprise phenyl, toluyl, xylyl, naphthyl and the like; suitable examples are stated below:

aroyl (for example benzoyl, toluoyl, xyloyl, naphthoyl, phthaloyl *etc.*);

aralkanoyl (for example phenylacetyl *etc.*);

aralkenoyl (for example cinnamoyl *etc.*);

aryloxyalkanoyl (for example phenoxyacetyl *etc.*);

arylthioalkanoyl (for example phenylthioacetyl *etc.*);

arylaminooalkanoyl (for example N-phenylglycyl *etc.*);

arenesulfonyl (for example benzenesulfonyl, tosyl or toluenesulfonyl, naphthalene-sulfonyl *etc.*);

aryloxycarbonyl (for example phenoxy carbonyl, naphthyloxy carbonyl *etc.*);

alkoxycarbonyl (for example benzyloxy carbonyl *etc.*);

arylcarbamoyl (for example phenylcarbamoyl, naphthylcarbamoyl *etc.*);

arylglyoxyloyl (for example phenylglyoxyloyl *etc.*).

In the above examples of acyl residues, the aromatic hydrocarbon moiety (in particular the aryl residue) and/or the aliphatic hydrocarbon moiety (in particular the alkane residue) may optionally comprise one or more suitable substituents, such as those which have already been stated as suitable substituents for the alkyl group or the alkane residue. Aromatic acyl residues having particular substituents which may in particular be mentioned and constitute examples of preferred aromatic acyl residues are aroyl substituted with halogen and hydroxy or with halogen and aryloxy, and aralkanoyl substituted with hydroxy, hydroxyimino, dihaloalkanoyloxyimino, together with arylthiocarbamoyl (for example phenylthiocarbamoyl *etc.*); arylcarbamimidoyl (for example phenylcarbamimidoyl *etc.*).

A heterocyclic acyl residue is taken to mean an acyl residue which originates from an acid with a heterocyclic group; these include:

5 heterocyclic carbonyl, in which the heterocyclic residue is an aromatic or aliphatic 5- to 6-membered heterocycle with at least one heteroatom from the group comprising nitrogen, oxygen and sulfur (for example thiophenyl, furyl, pyrrolocarbonyl, nicotinoyl *etc.*);

10 alkanoyl heterocycle, in which the heterocyclic residue is 5- to 6-membered and comprises at least one heteroatom from the group comprising nitrogen, oxygen and sulfur (for example thiophenylacetyl, furylacetyl, imidazolylpropionyl, tetrazolyl-acetyl, 2-(2-amino-4-thiazolyl)-2-methoxyiminoacetyl *etc.*) and the like.

15 In the above examples of heterocyclic acyl residues, the heterocycle and/or the aliphatic hydrocarbon moiety may optionally comprise one or more suitable substituents, such as those as have been stated to be suitable for alkyl and alkane groups.

20 "Alkyl" is a straight- or branched-chain alkyl residue with up to 9 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert.-butyl, pentyl, hexyl and the like.

25 "Hydroxyalkyl" is a straight- or branched-chain alkyl residue with up to 9 carbon atoms which comprises at least one hydroxyl group, preferably one or two hydroxyl groups.

30 "Alkenyl" includes straight- or branched-chain alkenyl groups with up to 9 carbon atoms, such as for example vinyl, propenyl (for example 1-propenyl, 2-propenyl), 1-methylpropenyl, 2-methylpropenyl, butenyl, 2-ethylpropenyl, pentenyl, hexenyl.

"Alkynyl" includes linear- or branched-chain alkynyl groups with up to 9 carbon atoms.

Cycloalkyl preferably denotes an optionally substituted C3-C7 cycloalkyl; possibly suitable substituents are *inter alia* alkyl, alkenyl, alkynyl, alkoxy (for example methoxy, ethoxy *etc.*), halogen (for example fluorine, chlorine, bromine *etc.*), nitro and the like.

Aryl is an aromatic hydrocarbon residue, such as phenyl, naphthyl *etc.*, which may optionally comprise one or more suitable substituents, such as alkyl, alkenyl, alkynyl, alkoxy (for example methoxy, ethoxy *etc.*), halogen (for example fluorine, chlorine, bromine *etc.*), nitro and the like.

"Aralkyl" includes mono-, di- and triphenylalkyls, such as benzyl, phenethyl, benzhydryl, trityl and the like, wherein the aromatic moiety may optionally comprise one or more suitable substituents, such as alkoxy (for example methoxy, ethoxy *etc.*), halogen (for example fluorine, chlorine, bromine *etc.*), nitro and the like.

"Alkylene" includes straight- or branched-chain alkylene groups which comprise up to 9 carbon atoms and may be represented by the formula




in which n is an integer from 1 to 9, such as methylene, ethylene, trimethylene, methylethylene, tetramethylene, 1-methyltrimethylene, 2-ethylethylene, pentamethylene, 2-methyltetramethylene, isopropylethylene, hexamethylene and the like; preferred alkylene residues have up to 4 carbon atoms and particularly preferred residues are those with 3 carbon atoms, such as for example trimethylene. The hydrogen atoms may be replaced by other substituents, such as for example halogen residues.

"Alkenylene" includes straight- or branched-chain alkenylene groups with up to 9 carbon atoms, which may be represented by the formula



in which n is an integer from 2 to 9, such as for example vinylene, propenylene (for example 1-propenylene, 2-propenylene), 1-methylpropenylene, 2-methylpropenylene, butenylene, 2-ethylpropenylene, pentenylene, hexenylene and the like; the alkenylene residue may particularly preferably comprise up to 5 carbon atoms and, in particular, 3 carbon atoms, such as for example 1-propenylene. The hydrogen atoms may be replaced by other substituents, such as for example halogen residues.

"Hydroxyalkylene" may include straight- or branched-chain alkylene residues which comprise up to 9 carbon atoms, wherein at least one selected carbon atom is substituted with a hydroxy group; these residues may be represented by the formula



in which n is an integer from 1 to 9 and z is an integer to which the relation $1 \leq z \leq n$ applies. Suitable examples of such hydroxyalkylene groups include hydroxymethylene, hydroxyethylene (for example 1-hydroxyethylene and 2-hydroxyethylene), hydroxytrimethylene (for example 1-hydroxytrimethylene, 2-hydroxytrimethylene and 3-hydroxytrimethylene), hydroxytetramethylene (for example 2-hydroxytetramethylene), 2-hydroxy-2-methyltrimethylene, hydroxypentamethylene (for example 2-hydroxypentamethylene), hydroxyhexamethylene (for example 2-hydroxyhexamethylene) and the like. A lower hydroxyalkylene comprising up to 4 carbon atoms is particularly preferred and in particular such a compound comprising 3 carbon atoms, such as for example 2-hydroxytrimethylene. The hydrogen atoms may be replaced by other substituents, such as for example halogen residues.

The residue X_4 may preferably be selected such that esters are formed on the phosphino group. Suitable examples of such esters of the formulae (I) and (II) include alkyl esters (for example methyl esters, ethyl esters, propyl esters, isopropyl esters, butyl esters, isobutyl esters, hexyl esters *etc.*);

aralkyl esters (benzyl esters, phenylethyl esters, benzhydryl esters, trityl esters *etc.*);

aryl esters (for example phenyl esters, tolyl esters, naphthyl esters *etc.*); aroylalkyl esters (for example phenacyl esters *etc.*); and silyl esters (for example of trialkylhalosilyl, dialkyldihalosilyl, alkyltrihalosilyl, dialkylarylhalosilyl, trialkoxyhalosilyl, dialkylaralkylhalosilyl, dialkoxydihalosilyl, trialkoxyhalosilyl *etc.*) and the like.

In the above esters, the alkane and/or arene moiety may optionally comprise at least one suitable substituent, such as halogen, alkoxy, hydroxy, nitro or the like.

X₄ is preferably a metal of main group I, II or III of the periodic system, ammonium, substituted ammonium or ammonium compounds which are derived from ethylenediamine or amino acids. In other words, the salt compounds of the organophosphorus compounds are formed with organic or inorganic bases (for example sodium salt, potassium salt, calcium salt, aluminium salt, ammonium salt, magnesium salt, triethylamine salt, ethanolamine salt, dicyclohexylamine salt, ethylenediamine salt, N,N'-dibenzylethylenediamine salt *etc.*) as are salts with amino acids (for example arginine salt, aspartic acid salt, glutamic acid salt *etc.*) and the like.

The compounds of the formula (I) or (II) used according to the invention may assume the protonated form thereof as an ammonium salt of organic or inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, methanesulfonic acid, p-toluenesulfonic acid, acetic acid, lactic acid, maleic acid, fumaric acid, oxalic acid, tartaric acid, benzoic acid *etc.*.

The compounds of the formula (I) or (II) used according to the invention permit the occurrence spatial isomers, for example for double bond-containing or chiral groups R₁, R₂, R₃, R₄, X₁, X₂, X₄ or A. The use according to the invention of the compounds includes all spatial isomers, both as pure substances and in the form of mixtures thereof.

The organophosphorus compounds are in particular suitable for the therapeutic and prophylactic treatment of human and animal infections which are caused by viruses, bacteria, uni- and multicellular parasites and fungi.

- 5 The compounds are active against unicellular parasites (protozoa), in particular against the causative organisms of malaria and sleeping sickness and of Chagas' disease, toxoplasmosis, amoebic dysentery, leishmaniasis, trichomoniasis, pneumocystosis, balantidiasis, cryptosporidiosis, sarcocytosis, acanthamoebosis, naeglerosis, coccidiosis, giardiasis and lambliasis.

10

They are accordingly in particular suitable for the prophylactic treatment of malaria and of sleeping sickness and of Chagas' disease, of toxoplasmosis, amoebic dysentery, leishmaniasis, trichomoniasis, pneumocystosis, balantidiasis, cryptosporidiosis, sarcocytosis, acanthamoebosis, naeglerosis, coccidiosis, giardiasis and lambliasis.

15

The active substances according to the invention may in particular be used against the following bacteria:

- 20 bacteria of the family *Propionibacteriaceae*, in particular of the genus *Propionibacterium*, in particular the species *Propionibacterium acnes*, bacteria of the family *Actinomycetaceae*, in particular of the genus *Actinomyces*, bacteria of the genus *Corynebacterium*, in particular the species *Corynebacterium diphtheriae* and *Corynebacterium pseudotuberculosis*, bacteria of the family *Mycobacteriaceae*, of the genus *Mycobacterium*, in particular the species *Mycobacterium leprae*,
25 *Mycobacterium tuberculosis*, *Mycobacterium bovis* and *Mycobacterium avium*, bacteria of the family *Chlamydiaceae*, in particular the species *Chlamydia trachomatis* and *Chlamydia psittaci*, bacteria of the genus *Listeria*, in particular the species *Listeria monocytogenes*, bacteria of the species *Erysipelthrix rhusiopathiae*, bacteria of the genus *Clostridium*, bacteria of the genus *Yersinia*, the species *Yersinia pestis*, *Yersinia pseudotuberculosis*, *Yersinia enterocolitica* and *Yersinia ruckeri*,
30 bacteria of the family *Mycoplasmataceae*, of the genera *Mycoplasma* and *Ureaplasma*, in particular the species *Mycoplasma pneumoniae*, bacteria of the genus

Brucella, bacteria of the genus *Bordetella*, bacteria of the genus *Campylobacter*, in particular the species *Campylobacter jejuni*, *Campylobacter coli* and *Campylobacter fetus*, bacteria of the genus *Helicobacter*, in particular the species *Helicobacter pylori*. bacteria of the families *Spirochaetaceae* and *Leptospiraceae*, in particular the genera *Treponema*, *Borrelia* and *Leptospira*, in particular *Borrelia burgdorferi*, bacteria of the genus *Actinobacillus*, bacteria of the family *Legionellaceae*, of the genus *Legionella*, bacteria of the family *Rickettsiaceae* and the family *Bartonellaceae*, bacteria of the genera *Nocardia* and *Rhodococcus* and bacteria of the genus *Dermatophilus*.

Organophosphorus compounds and the derivatives thereof are consequently suitable for treating diphtheria, acne vulgaris, listerioses, swine erysipelas in animals, gas gangrene in humans and animals, malignant oedema in humans and animals, tuberculosis in humans and animals, leprosy and further mycobacterioses in humans and animals, paratuberculosis in animals, plague, mesenteric lymphadenitis and pseudotuberculosis in humans and animals, cholera, legionnaires' disease, borreliosis in humans and animals, leptospiroses in humans and animals, syphilis, *Campylobacter* enteritis infections in humans and animals, *Moraxella* keratoconjunctivitis and serositis in animals, brucellosis of animals and humans, anthrax in humans and animals, actinomycosis in humans and animals, streptotrichoses, psittacosis/ornithosis in animals. Q fever, ehrlichiosis.

Use is furthermore effective in the eradication of *Helicobacter* in ulcers of the gastrointestinal tract.

Combinations with another antibiotic may also be used to treat the above-stated diseases. Isoniazid, rifampicin, ethambutol, pyrazinamide, streptomycin, protionamide and dapsone are in particular suitable for combination preparations with other anti-infective agents for the treatment of tuberculosis.

The active substances according to the invention are furthermore usable in infections with the following viruses:

Parvoviridae: parvoviruses, dependoviruses, densoviruses, *Adenoviridae*: adenoviruses, mastadenoviruses, aviadenoviruses, *Papovaviridae*: papovaviruses, in particular papillomaviruses ("wart" viruses), polyomaviruses, in particular JC virus, BK virus and miopapovaviruses, *Herpesviridae*: all herpesviruses, in particular herpes simplex viruses, varicella-zoster viruses, human cytomegalovirus, Epstein-Barr viruses, all human herpesviruses, human herpesvirus 6, human herpesvirus 7, human herpesvirus 8, *Poxviridae*: poxviruses, orthopoxviruses, parapoxviruses, molluscum contagiosum virus, aviviruses, capriviruses, leporipoxviruses, all primarily hepatotropic viruses, hepatitisviruses: hepatitis A viruses, hepatitis B viruses, hepatitis C viruses, hepatitis D viruses, hepatitis E viruses, hepatitis F viruses, hepatitis G viruses, hepadnaviruses: all hepatitisviruses, hepatitis B virus, hepatitis D viruses, *Picornaviridae*: picornaviruses, all enteroviruses, all polioviruses, all coxsackieviruses, all echoviruses, all rhinoviruses, hepatitis A virus, aphthoviruses, *Calciviridae*: hepatitis E viruses, *Reoviridae*: reoviruses, orbiviruses, rotaviruses, *Togaviridae*: togaviruses, alphaviruses, rubiviruses, pestiviruses, rubellavirus, *Flaviviridae*: flaviviruses, FSME virus, hepatitis C virus, *Orthomyxoviridae*: all influenza viruses, *Paramyxoviridae*: paramyxoviruses, morbillivirus, pneumovirus, measles virus, mumps virus, *Rhabdoviridae*: rhabdoviruses, rabies virus, lyssavirus, vascular stomatitisvirus, *Coronaviridae*: coronaviruses, *Bunyaviridae*: bunyaviruses, nairovirus, phlebovirus, uukuvirus, hantavirus, hantaan virus, *Arenaviridae*: arenaviruses, lymphocytic choriomeningitis virus, *Retroviridae*: retroviruses, all HTL viruses, human T-cell leukaemia virus, oncornaviruses, spumaviruses, lentiviruses, all HI viruses, *Filoviridae*: Marburg and Ebola virus, slow-virus infections, prions, oncoviruses and leukaemia viruses.

The organophosphorus compounds used according to the invention are consequently suitable for combating the following viral infections:

eradication of papillomaviruses to prevent tumours, in particular tumours of the reproductive organs caused by papillomaviruses in humans, eradication of JC viruses and BK viruses, eradication of herpesviruses, eradication of human herpesvirus 8 to treat Kaposi's sarcoma, eradication of cytomegaloviruses before transplantations,

eradication of Epstein-Barr viruses before transplantation and to prevent tumours associated with Epstein-Barr viruses, eradication of hepatitis viruses to treat chronic liver disease and to prevent liver tumours and cirrhosis of the liver, eradication of coxsackieviruses in cardiomyopathy, eradication of coxsackieviruses in diabetes mellitus patients, eradication of immunodeficiency viruses in humans and animals, treatment of accompanying infections in AIDS patients, treatment of respiratory tract inflammation of viral causation (laryngeal papilloma, hyperplasia, rhinitis, pharyngitis, bronchitis, pneumonia), of the sensory organs (keratoconjunctivitis), of the nervous system (poliomyelitis, meningoencephalitis, encephalitis, subacute sclerosing panencephalitis, SSPE, progressive multifocal leukoencephalopathy, lymphocytic choriomeningitis), of the gastrointestinal tract (stomatitis, gingivostomatitis, oesophagitis, gastritis, gastroenteritis, diarrhoea), of the liver and gall system (hepatitis, cholangitis, hepatocellular carcinoma), of the lymphatic tissue (mononucleosis, lymphadenitis), of the haemopoietic system, of the reproductive organs (mumps orchitis), of the skin (warts, dermatitis, herpes labialis, herpes febrilis, herpes zoster, shingles), of the mucous membranes (papillomas, conjunctival papillomas, hyperplasia, dysplasia), of the cardiovascular system (arteriitis, myocarditis, endocarditis, pericarditis), of the kidney/urinary system, of the reproductive organs (anogenital lesions, warts, genital warts, sharp condylomas, dysplasia, papillomas, cervical dysplasia, condyloma acuminatum, epidermodysplasia verruciformis), of the locomotory organs (myositis, myalgia), treatment of foot-and-mouth disease in cloven-hoofed animals, of Colorado tick fever, Dengue syndrome, of haemorrhagic fever, of early summer meningoencephalitis (FSME) and of yellow fever.

The described compounds, *i.e.* the organophosphorus compounds of the formula (I) and (II) and esters and amides thereof on the phosphino group and salts thereof exhibit strong cytotoxic activity against uni- and multicellular parasites, in particular against the causative organisms of malaria and sleeping sickness. The compounds used according to the invention are accordingly usable for the treatment of infective diseases which are caused in humans and animals by viruses, bacteria, parasites and fungi. The compounds are also suitable for the prevention of diseases which are

caused by viruses, bacteria, parasites and fungi, in particular for the prophylactic treatment of malaria and of sleeping sickness.

The organophosphorus compounds used according to the invention, which generally include for this purpose pharmaceutically acceptable salts, amides, esters, a salt of such an ester or also compounds which, on administration, provide the compounds used according to the invention as metabolites or breakdown products (also known as "prodrugs"), may be formulated for administration in any suitable manner analogous to known agents having an antiinfective action (mixed with a non-toxic, pharmaceutically acceptable excipient).

Pharmaceutically acceptable salts of the compounds include salts which the compounds of the formulae (I) and (II) used according to the invention form in their protonated form as an ammonium salt of inorganic or organic acids, such as hydrochloric acid, sulfuric acid, citric acid, maleic acid, fumaric acid, tartaric acid, p-toluenesulfonic acid.

Particularly pharmaceutically suitable salts are also those formed by suitable selection of X_4 , such as sodium salt, potassium salt, calcium salt, ammonium salt, ethanolamine salt, triethylamine salt, dicyclohexylamine salt and salts of an amino acid such as arginine salt, aspartic acid salt, glutamic acid salt.

Use of the above-stated substances is in particular suitable for the production of pharmaceutical preparations against bacterial diseases or for the prevention thereof or for the production of herbicides.

The activity of the substances is determined using a test system. This system is based upon *in vitro* measurement of the inhibition of growth of bacteria, parasites, viruses, fungi or plants. Test methods known to the person skilled in the art are in part used for this purpose.

For example, antimalarial activity is determined by measuring the inhibition of the growth of malaria parasites in blood cultures.

5 Antibacterial activity is determined on the basis of measuring the inhibition of bacterial growth on nutrient media and in liquid cultures.

Antiviral activity is determined on the basis of the formation of viral elements in cell cultures.

10 Some of the microorganisms which are to be investigated may only be investigated in animal models. In this case, we will then use the appropriate models.

Substances which exhibit activity in *in vitro* measurement systems are then further investigated in *in vivo* models.

15 The antiparasitic, antiviral, fungicidal or antibacterial activity is further evaluated in the appropriate animal models.

Screening for herbicidal activity is determined by means of algal systems and measurement of isoprene emissions from plants under standard conditions.

20 The pharmaceutically active agents may be prepared in dosage units in the form of pharmaceutical preparations. This means that the preparation is in the form of individual components, for example tablets, coated tablets, capsules, pills, suppositories and ampoules, the active substance content of which corresponds to a fraction or multiple of an individual dose. The dosage units may contain, for example
25 1, 2, 3 or 4 individual doses or 1/2, 1/3 or 1/4 of an individual dose. An individual dose preferably contains the quantity of active substance which is administered at one time and usually corresponds to a whole, half, third or quarter of a daily dose.

30 Non-toxic, inert, pharmaceutically suitable excipients should be taken to mean solid, semi-solid or liquid diluents, fillers and formulation auxiliaries of all kinds.

Preferred pharmaceutical preparations which may be mentioned are tablets, coated tablets, capsules, pills, granules, suppositories, solutions, suspensions and emulsions, pastes, ointments, gels, creams, lotions, powders and sprays. Tablets, coated tablets, capsules, pills and granules may contain the active substances together with conventional excipients, such as (a) fillers and extenders, for example starches, lactose, cane sugar, glucose, mannitol and silica, (b) binders, for example carboxymethylcellulose, alginates, gelatine, polyvinylpyrrolidone, (c) humectants, for example glycerol, (d) suspending agents, for example agar-agar, calcium carbonate and sodium carbonate, (e) dissolution retardants, for example paraffin and (f) resorption accelerators, for example quaternary ammonium compounds, (g) wetting agents, for example cetyl alcohol, glycerol monostearate, (h) adsorbents, for example kaolin and bentonite and (i) lubricants, for example talcum, calcium and magnesium stearate and solid polyethylene glycols or mixtures of the substances stated in (a) to (i).

The tablets, coated tablets, capsules, pills and granules may be provided with conventional coatings and shells optionally containing opacifying agents and may also be composed such that they release the active substances only with a delay or preferably in a particular part of the intestinal tract, wherein polymeric substances and waxes may, for example, be used as the matrices.

The active substance or substances, optionally together with one or more of the above-stated excipients, may also be present in microencapsulated form.

In addition to the active substance or substances, suppositories may contain conventional water-soluble or water-insoluble excipients, for example polyethylene glycols, fats, for example cocoa butter and higher esters (for example C14 alcohol with C16 fatty acid) or mixtures of these substances.

In addition to the active substance or substances, ointments, pastes, creams and gels may contain conventional excipients, for example animal and vegetable fats, waxes,

paraffins, starch, gum tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silica, talcum and zinc oxide or mixtures of these substances.

5 In addition to the active substance or substances, powders and sprays may contain conventional excipients, for example lactose, talcum, silica, aluminium hydroxide, calcium silicate and polyamide powder or mixtures of these substances. Sprays may additionally contain conventional propellants, for example chlorofluorocarbons.

10 In addition to the active substance or substances, solutions and emulsions may contain conventional excipients. such as solvents, solubilising agents and emulsifiers, for example water, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils, in particular cottonseed oil, peanut oil, corn oil, olive oil, castor oil and sesame oil. glycerol, glycerol formal, tetrahydrofurfuryl alcohol, polyethylene glycols and
15 sorbitan fatty acid esters or mixtures of these substances.

For parenteral administration. the solutions and emulsions may also be present in sterile, isotonic form.

20 In addition to the active substance or substances, suspensions may contain conventional excipients. such as liquid diluents, for example water, ethyl alcohol, propylene glycol, suspending agents, for example ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminium metahydroxide, bentonite. agar-agar and gum tragacanth or mixtures of these
25 substances.

The stated formulations may also contain colorants, preservatives and odour- or flavour-enhancing additives, for example peppermint oil and eucalyptus oil, and sweeteners, for example saccharin.

30

The active substances of the formulae (I) and (II) should preferably be present in the pharmaceutical preparations listed above in a concentration of approx. 0.1 to 99.5 wt.%, preferably from approx. 0.5 to 95 wt.%, of the complete mixture.

- 5 Apart from the compounds of the formulae (I) and (II), the pharmaceutical preparations may also contain further pharmaceutical active substances.

The compounds may be used together with hitherto described substances having antibacterial, antiviral, antimycotic and antiparasitic properties. Such substances in particular include compounds which have already been used in therapeutic applications or are still used. Substances which are suitable for this purpose are in particular those listed in the Red List or in Simon/Stille, *Antibiotika-Therapie in Klinik und Praxis*, 9th edition, 1998, Schatauer Verlag, or on the Internet at <http://www.customs.treas.gov/imp-exp/rulings/harmoniz/hrm129.html>. The derivatives may in particular be present with penicillins, benzylpenicillin (penicillin G), phenoxypenicillins, isoxazolympenicillins, aminopenicillins, ampicillin, amoxicillin, bacampicillin, carboxypenicillin, ticarcillin, temocillin, acylaminopenicillins, mezlocillin, mezlocillin, piperacillin, apalcillin, mecillinam, cephalosporins, cefazolin group, cefuroxime group, cefoxitin group, cefoxitin, cefotetan, cefmetazole, latamoxef, flomoxef, cefotaxime group, ceftazidime group, ceftazidime, cefpirome, cefepime, conventional cephalosporins, cefsulodin, cefoperazone, oral cephalosporins of the cephalixin group, loracarbef, cefprozil, new broad-spectrum oral cephalosporins, cefixime, cefpodoxime-proxetil, cefuroxime-axetil, cefetamet, cefotiam-hexetil, cefdinir, cefbuten, other β -lactam antibiotics, carbapenem, imipenem/cilastatin, meropenem, biapenem, aztreonam, β -lactamase inhibitors, clavulanic acid/amoxicillin, clavulanic acid/ticarcillin, sulbactam/ampicillin, tazobactam/piperacillin, tetracyclines, oxytetracycline, rolitetracycline, doxycycline, minocycline, chloramphenicol, aminoglycosides, gentamicin, tobramycin, netilmicin, amikacin, spectinomycin, macrolides, erythromycin, clarithromycin, roxithromycin, azithromycin, dirithromycin, spiramycin, josamycin, lincosamides, clindamycin, fusidic acid, glycopeptide antibiotics, vancomycin, teicoplanin, pristinamycin derivatives, fosfomycin, antimicrobial folic acid antagonists, sulfonamides,

10
15
20
25
30

co-trimoxazole, trimethoprim, other diaminopyrimidine-sulfonamide combinations, nitrofurans, nitrofurantoin, nitrofurazone, gyrase inhibitors (quinolones), norfloxacin, ciprofloxacin, ofloxacin, sparfloxacin, enoxacin, fleroxacin, pefloxacin, lomefloxacin, Bay Y3118, nitroimidazoles, antimycobacterial agents, isoniazid, rifampicin, 5 rifabutin, ethambutol, pyrazinamide, streptomycin, capreomycin, prothionamide, terizidone, dapsone, clofazimine, topical antibiotics, bacitracin, tyrothricin, polymyxins, neomycin, kanamycin, paromomycin, mupirocin, antiviral agents, acyclovir, ganciclovir, azidothymidine, didanosine, zalcitabine, thiacytidine, stavudine, ribavirin, idoxuridine, trifluridine, foscarnet, amantadine, interferons, 10 tibol derivatives, proteinase inhibitors, antimycotics, polyenes, amphotericin B, nystatin, natamycin, azoles, azoles for septic therapy, miconazole, ketoconazole, itraconazole, fluconazole, UK-109,496, azoles for topical use, clotrimazole, econazole, isoconazole, oxiconazole, bifonazole, flucytosine, griseofulvin, ciclopirox olamine, tolnaftate, naftifine, terbinafine, amorolfine, anthraquinones, betulinic acid, semianthraquinones, 15 xanthenes, naphthoquinones, arylamino alcohols, quinine, quinidines, mefloquine, halofantrine, chloroquine, amodiaquine, acridine, benzonaphthiridine, mepacrine, pyronaridine, dapsone, sulfonamides, sulfadoxine, sulfalenes, trimethoprim, proguanil, chlorproguanil, diaminopyrimidines, pyrimethamine, primaquine, aminoquinolines, WR 238,605, tetracycline, doxycycline, clindamycin, norfloxacin, 20 ciprofloxacin, ofloxacin, artemisinin, dihydroartemisinin, 10b artemether, arteether, aresunate, atovaquone, suramin, melarsoprol, nifurtimox, stibogluconate sodium, pentamidine, amphotericin B, metronidazole, clioquinol, mebendazole, niclosamide, praziquantel, pyrantel, tiabendazole, diethylcarbamazine, ivermectin, bithionol, oxamniquine, metrifonate, piperazine, embonate.

25

The organophosphorus compounds may furthermore be present in the pharmaceutical preparations in combination with sulfonamide, sulfadoxine, artemisinin, atovaquone, quinine, chloroquine, hydroxychloroquine, mefloquine, halofantrine, pyrimethamine, artesin, tetracyclines, doxycycline, proguanil, metronidazole, praziquantel, 30 niclosamide, mebendazole, pyrantel, tiabendazole, diethylcarbamazine, piperazine, pyrivinium, metrifonate, oxamniquine, bithionol or suramin or two or more of these substances.

The above-stated pharmaceutical preparations are produced in the conventional manner using known methods, for example by mixing the active substance or substances with the excipient or excipients.

5

The stated preparations may be administered to humans and animals orally, rectally, parenterally (intravenously, intramuscularly, subcutaneously), intracisternally, intravaginally, intraperitoneally, topically (powders, ointments, drops) and for the treatment of infections in cavities, body cavities. Suitable preparations which may be considered are solutions for injections, solutions and suspensions for oral therapy, gels, infusion formulations, emulsions, ointments or drops. Topical treatment may be performed using ophthalmological and dermatological formulations, silver and other salts, ear drops, eye ointments, powders or solutions. Administration to animals may also be achieved via the feed or drinking water in suitable formulations. Gels, pulverulent formulations, powders, tablets, controlled-release tablets, premixes, concentrates, granules, pellets, tablets, boli, capsules, aerosols, sprays, inhalation formulations may also be used in humans and animals. The compounds used according to the invention may also be incorporated into other supports, such as for example plastics (plastic chains for topical treatment), collagen or bone cement.

20

It has in general proved advantageous in both human and veterinary medicine to administer the active substances of the formulae (I) and (II) in total quantities of approx. 0.05 to approx. 600, preferably of 0.5 to 200 mg/kg body weight per 24 hours, optionally in the form of two or more individual doses in order to achieve the desired results. An individual dose preferably contains the active substance or substances in quantities of approx. 1 to approx. 200, in particular of 1 to 60 mg/kg body weight. It may, however, be necessary to deviate from the stated dosages, in particular as a function of the nature and body weight of the patient to be treated, the nature and severity of the disease, the nature of the preparations and the route of administration of the drug and the period of time over which administration is performed.

30

- 21 -


5 In some cases, it may be sufficient to use less than the above-stated quantity of active substance, while in other cases more than the above-stated quantity of active substance must be used. The person skilled in the art will use his/her skill to determine the optimum dosage and route of administration required in each particular case.

10 The compounds according to the invention may be given to animals in conventional concentrations and preparations together with feed or feed preparations or with drinking water.

The compounds used according to the invention are furthermore ideally usable as bactericides, fungicides and herbicides in plants.

Claims

1. Use of organophosphorus compounds of the general formula (I)



5 in which R₁ and R₂ are identical or different and are selected from the group consisting of hydrogen, substituted and unsubstituted alkyl, substituted and unsubstituted hydroxyalkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted aryl, substituted and unsubstituted acyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted aralkyl, substituted and unsubstituted heterocyclic residue, halogen, OX₁ and OX₂,

10 wherein X₁ and X₂ may be identical or different and are selected from the group consisting of hydrogen, substituted and unsubstituted alkyl, substituted and unsubstituted hydroxyalkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted aryl, substituted and unsubstituted acyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted aralkyl, substituted and unsubstituted heterocyclic residue.

20 A is selected from the group consisting of an alkylene residue, an alkenyl residue and a hydroxyalkylene residue,


R₃ is selected from the group consisting of hydrogen, substituted and unsubstituted alkyl, substituted and unsubstituted hydroxyalkyl, substituted and unsubstituted aryl, substituted and unsubstituted acyl, substituted and unsubstituted aralkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclic residue, halogen,

25 R₄ is selected from the group consisting of hydrogen, substituted and unsubstituted alkyl, substituted and unsubstituted hydroxyalkyl, substituted

and unsubstituted aryl, substituted and unsubstituted acyl, substituted and unsubstituted aralkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclic residue, halogen, OX₄,
5 wherein X₄ is selected from the group consisting of hydrogen, substituted and unsubstituted alkyl, substituted and unsubstituted hydroxyalkyl, substituted and unsubstituted aryl, substituted and unsubstituted aralkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclic residue, a
10 silyl, a cation of an organic and inorganic base, in particular of a metal of main group I, II or III of the periodic system, ammonium, substituted ammonium and ammonium compounds which are derived from ethylenediamine or amino acids,
and pharmaceutically acceptable salts, esters and amides and salts of the
15 esters, or alternatively compounds which, on administration, provide the compounds to be used according to the invention as metabolites or breakdown products,
for the production of pharmaceutical preparations for the therapeutic and prophylactic treatment of infections in humans and animals caused by
20 parasites, fungi, viruses and bacteria selected from the group consisting of bacteria of the family *Propionibacteriaceae*, in particular of the genus *Propionibacterium*, in particular the species *Propionibacterium acnes*, bacteria of the family *Actinomycetaceae*, in particular of the genus *Actinomyces*, bacteria of the genus *Corynebacterium*, in particular the species
25 *Corynebacterium diphtheriae* and *Corynebacterium pseudotuberculosis*, bacteria of the family *Mycobacteriaceae*, of the genus *Mycobacterium*, in particular the species *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycobacterium bovis* and *Mycobacterium avium*, bacteria of the family *Chlamydiaceae*, in particular the species *Chlamydia trachomatis* and
30 *Chlamydia psittaci*, bacteria of the genus *Listeria*, in particular the species *Listeria monocytogenes*, bacteria of the species *Erysipelthrix rhusiopathiae*, bacteria of the genus *Clostridium*, bacteria of the genus *Yersinia*, the species

Yersinia pestis, *Yersinia pseudotuberculosis*, *Yersinia enterocolitica* and *Yersinia ruckeri*, bacteria of the family *Mycoplasmataceae*, of the genera *Mycoplasma* and *Ureaplasma*, in particular the species *Mycoplasma pneumoniae*, bacteria of the genus *Brucella*, bacteria of the genus *Bordetella*, bacteria of the genus *Campylobacter*, in particular the species *Campylobacter jejuni*, *Campylobacter coli* and *Campylobacter fetus*, bacteria of the genus *Helicobacter*, in particular the species *Helicobacter pylori*, bacteria of the families *Spirochaetaceae* and *Leptospiraceae*, in particular the genera *Treponema*, *Borrelia* and *Leptospira*, in particular *Borrelia burgdorferi*, bacteria of the genus *Actinobacillus*, bacteria of the family *Legionellaceae*, of the genus *Legionella*, bacteria of the family *Rickettsiaceae* and the family *Bartonellaceae*, bacteria of the genera *Nocardia* and *Rhodococcus*, bacteria of the genus *Dermatophilus*, and as a fungicide, bactericide and herbicide in plants.

2. Use according to claim 1, characterised in that the organophosphorus compounds are of the formula (II)



wherein

- X₁ is selected from the group consisting of hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic residue; R₂, R₃, R₄ and A have the same meaning as in formula (I).
3. Use according to claim 2, characterised in that R₂ is an acyl residue, in particular a formyl or acetyl residue,

- 25 -

R_3 is selected from the group consisting of hydrogen, methyl and ethyl,
 R_4 is selected from the group consisting of hydrogen, methyl, ethyl and OX_4 ,
 X_4 is selected from the group consisting of hydrogen, sodium, potassium,
methyl and ethyl,

X_1 is H

and A is selected from the group consisting of alkylene, alkenylene or
hydroxyalkylene.

4. Use according to one of the preceding claims, characterised in that A forms a
chain of three carbon atoms between the phosphorus atom and the nitrogen
atom.

5. Use according to claim 2,
characterised in that

X_4 is selected from the group consisting of hydrogen, ammonium and metals
of main groups I and II of the periodic system, preferably sodium, potassium,
calcium or magnesium, ammonium compounds, which are derived from
ethylenediamine or amino acids, preferably ethanolamine, ethylenediamine,
 N,N -dibenzylethylenediamine and arginine.

6. Use according to one of claims 2 to 5,
characterised in that

R_2 is an acyl residue and A an alkylene residue, wherein R_2 is preferably
formed by formyl or acetyl and A preferably by propylene, propenylene and
hydroxypropylene.

7. Use according to one of the preceding claims for the production of
pharmaceutical preparations for the treatment of infections caused by bacteria,
viruses, fungi or uni- or multicellular parasites.

8. Use according to claim 7 for the production of pharmaceutical preparations for
the treatment of infections caused by bacteria selected from the group

- consisting of bacteria of the family *Propionibacteriaceae*, in particular of the genus *Propionibacterium*, in particular the species *Propionibacterium acnes*, bacteria of the family *Actinomycetaceae*, in particular of the genus *Actinomyces*, bacteria of the genus *Corynebacterium*, in particular the species
- 5 *Corynebacterium diphtheriae* and *Corynebacterium pseudotuberculosis*, bacteria of the family *Mycobacteriaceae*, of the genus *Mycobacterium*, in particular the species *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycobacterium bovis* and *Mycobacterium avium*, bacteria of the family *Chlamydiaceae*, in particular the species *Chlamydia trachomatis* and
- 10 *Chlamydia psittaci*, bacteria of the genus *Listeria*, in particular the species *Listeria monocytogenes*.
9. Use according to claim 7 for the production of pharmaceutical preparations for the treatment of infections caused by viruses selected from the group
- 15 consisting of *Parvoviridae*, in particular parvoviruses, dependoviruses, densoviruses, *Adenoviridae*, in particular adenoviruses, mastadenoviruses, aviadenoviruses, viruses of the genus *Papovaviridae*, in particular papovaviruses, in particular papillomaviruses ("wart" viruses), polyomaviruses, in particular JC virus, BK virus and miopapovaviruses,
- 20 viruses of the genus *Herpesviridae*, in particular herpes simplex viruses, varicella-zoster viruses, human cytomegalovirus, Epstein-Barr viruses, human herpesvirus 6, human herpesvirus 7, human herpesvirus 8, viruses of the genus *Poxviridae*, in particular poxviruses, orthopoxviruses, parapoxviruses, molluscum contagiosum virus, aviruses, capriviruses, leporipoxviruses,
- 25 primarily hepatotropic viruses, in particular hepatitisviruses, such as hepatitis A viruses, hepatitis B viruses, hepatitis C viruses, hepatitis D viruses, hepatitis E viruses, hepatitis F viruses, hepatitis G viruses, hepadnaviruses, in particular all hepatitisviruses, such as hepatitis B virus, hepatitis D viruses, viruses of the genus *Picornaviridae*, in particular picornaviruses, all
- 30 enteroviruses, all polioviruses, all coxsackieviruses, all echoviruses, all rhinoviruses, hepatitis A virus, aphthoviruses, viruses of the genus *Calciviridae*, in particular hepatitis E viruses, viruses of the genus *Reoviridae*,

- orbiviruses, rotaviruses, viruses of the genus *Togaviridae*, in particular togaviruses, alphaviruses, rubiviruses, pestiviruses, rubellavirus, viruses of the genus *Flaviviridae*, in particular flaviviruses, FSME virus, hepatitis C virus. viruses of the genus *Orthomyxoviridae*, in particular influenza viruses, viruses of the genus *Paramyxoviridae*, in particular paramyxoviruses, morbillivirus. pneumovirus, measles virus, mumps virus, viruses of the genus *Rhabdoviridae*, in particular rhabdoviruses, rabies virus, lyssavirus, vascular stomatitisvirus, viruses of the genus *Coronaviridae*, in particular coronaviruses, viruses of the genus *Bunyaviridae*, in particular bunyaviruses, nairovirus, phlebovirus, uukuvirus, hantavirus, hantaan virus, viruses of the genus *Arenaviridae*, in particular arenaviruses, lymphocytic choriomeningitis virus, viruses of the genus *Retroviridae*, in particular retroviruses, all HTL viruses, human T-cell leukaemia virus, oncornaviruses, spumaviruses, lentiviruses, all HI viruses, viruses of the genus *Filoviridae*, in particular Marburg and Ebola virus, slow viruses, prions, oncoviruses and leukaemia viruses.
10. Use according to claim 7 for the production of pharmaceutical preparations for the prevention and treatment of infections caused by unicellular parasites, namely the causative organisms of malaria and sleeping sickness and of Chagas' disease, toxoplasmosis, amoebic dysentery, leishmaniasis, trichomoniasis, pneumocystosis, balantidiasis, cryptosporidiosis, sarcocytosis, acanthamoebosis, naeglerosis, coccidiosis, giardiasis and lambliaisis.
11. Use according to one of claims 1 to 10 characterised in that the pharmaceutical preparation comprises an effective content of at least one organophosphorus compound and a pharmaceutically acceptable excipient.
12. Use according to claim 11, characterised in that the pharmaceutical preparation comprises at least one further pharmaceutical active substance.

13. Use according to claim 12, characterised in that the pharmaceutical preparation moreover comprises one or more constituents of the group consisting of sulfonamide, sulfadoxine, artemisinin, atovaquone, quinine, chloroquine, hydroxychloroquine, mefloquine, halofantrine, pyrimethamine, artesin, tetracyclines, doxycycline, proguanil, metronidazole, praziquantel, niclosamide, mebendazole, pyrantel, tiabendazole, diethylcarbazine, piperazine, pyriminium, metrifonate, oxamniquine, bithionol and suramin.
14. Use according to claim 12, characterised by one or more constituents of the group consisting of penicillins, benzylpenicillin (penicillin G), phenoxypenicillins, isoxazolylic penicillins, aminopenicillins, ampicillin, amoxicillin, bacampicillin, carboxypenicillin, ticarcillin, temocillin, acylaminopenicillins, azlocillin, mezlocillin, piperacillin, apalcillin, mecillinam, cephalosporins, cefazolin group, cefuroxime group, cefoxitin group, cefoxitin, cefotetan, cefmetazole, latamoxef, flomoxef, cefotaxime group, ceftazidime, ceftazidime group, ceftazidime, ceftiofime, cefepime, conventional cephalosporins, cefsulodin, cefoperazone, oral cephalosporins of the cephalixin group, loracarbef, cefprozil, new broad-spectrum oral cephalosporins, cefixime, cefpodoxime-proxetil, cefuroxime-axetil, cefetamet, cefotiam-hexetil, cefdinir, ceftibuten, other β -lactam antibiotics, carbapenem, imipenem/cilastatin, meropenem, biapenem, aztreonam, β -lactamase inhibitors, clavulanic acid/amoxicillin, clavulanic acid/ticarcillin, sulbactam/ampicillin, tazobactam/piperacillin, tetracyclines, oxytetracycline, rolitetracycline, doxycycline, minocycline, chloramphenicol, aminoglycosides, gentamicin, tobramycin, netilmicin, amikacin, spectinomycin, macrolides, erythromycin, clarithromycin, roxithromycin, azithromycin, dirithromycin, spiramycin, josamycin, lincosamides, clindamycin, fusidic acid, glycopeptide antibiotics, vancomycin, teicoplanin, pristinamycin derivatives, fosfomycin, antimicrobial folic acid antagonists, sulfonamides, co-trimoxazole, trimethoprim, other diaminopyrimidine-sulfonamide combinations, nitrofurans, nitrofurantoin, nitrofurazone, gyrase inhibitors (quinolones), norfloxacin, ciprofloxacin,

5 ofloxacin, sparfloxacin, enoxacin, fleroxacin, pefloxacin, lomefloxacin, Bay Y3118, nitroimidazoles, antimycobacterial agents, isoniazid, rifampicin, rifabutin, ethambutol, pyrazinamide, streptomycin, capreomycin, prothionamide, terizidone, dapsone, clofazimine, topical antibiotics,
10 bacitracin, tyrothricin, polymyxins, neomycin, kanamycin, paromomycin, mupirocin, antiviral agents, acyclovir, ganciclovir, azidothymidine, didanosine, zalcitabine, thiacytidine, stavudine, ribavirin, idoxuridine, trifluridine, foscarnet, amantadine, interferons, tibol derivatives, proteinase inhibitors, antimycotics, polyenes, amphotericin B, nystatin, natamycin,
15 azoles, azoles for septic therapy, miconazole, ketoconazole, itraconazole, fluconazole, UK-109,496, azoles for topical use, clotrimazole, econazole, isoconazole, oxiconazole, bifonazole, flucytosine, griseofulvin, ciclopirox olamine, tolnafate, naftifine, terbinafine, amorolfine, anthraquinones, betulinic acid, semianthraquinones, xanthones, naphthoquinones, arylamino
20 alcohols, quinine, quinidines, mefloquine, halofantrine, chloroquine, amodiaquine, acridine, benzonaphthyridine, mepacrine, pyronaridine, dapsone, sulfonamides, sulfadoxine, sulfalenes, trimethoprim, proguanil, chlorproguanil, diaminopyrimidines, pyrimethamine, primaquine, aminoquinolines, WR 238,605, tetracycline, doxycycline, clindamycin,
25 norfloxacin, ciprofloxacin, ofloxacin, artemisinin, dihydroartemisinin, 10b artemether, arteether, atresunate, atovaquone, suramin, melarsoprol, nifurtimox, stibogluconate sodium, pentamidine, amphotericin B, metronidazole, clioquinol, mebendazole, niclosamide, praziquantel, pyrantel, tiabendazole, diethylcarbamazine, ivermectin, bithionol, oxamniquine,
metrifonate, piperazine, embonate.

Translator's comments:

p.14, final para.-p.15, para.1: "vorliegen" has been assumed to have been omitted from after the list of antibiotics *etc.* and "be present" has accordingly been inserted in the translation.

p.19, claim 5: "aus der" has been assumed to have been omitted from before "Gruppe" and the phrase has accordingly been translated as "from the group", *c.f.* p.19, claim 3.

PCT

WELTORGANISATION FÜR GEISTIGES EIGENTUM
Internationales Büro




INTERNATIONALE ANMELDUNG VERÖFFENTLICHT NACH DEM VERTRAG ÜBER DIE
INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES PATENTWESENS (PCT)

<p>(51) Internationale Patentklassifikation 7 : A61K 31/00</p>	<p>A2</p>	<p>(11) Internationale Veröffentlichungsnummer: WO 00/16757 (43) Internationales Veröffentlichungsdatum: 30. März 2000 (30.03.00)</p>
<p>(21) Internationales Aktenzeichen: PCT/EP99/07054 (22) Internationales Anmeldedatum: 22. September 1999 (22.09.99) (30) Prioritätsdaten: 198 43 222.4 22. September 1998 (22.09.98) DE (71)(72) Anmelder und Erfinder: JOMAA, Hassan [DE/DE]; Breslauer Strasse 24, D-35398 Giessen (DE). (74) Anwälte: PANTEN, Kirsten usw.; Reichel und Reichel, Parkstrasse 13, D-60322 Frankfurt am Main (DE).</p>		<p>(81) Bestimmungsstaaten: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO Patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), eurasisches Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), europäisches Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI Patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Veröffentlicht <i>Ohne internationalen Recherchenbericht und erneut zu veröffentlichen nach Erhalt des Berichts.</i></p>

(54) Title: USE OF ORGANOPHOSPHOROUS COMPOUNDS FOR PRODUCING MEDICAMENTS FOR THE THERAPEUTIC AND PROPHYLACTIC TREATMENT OF INFECTIONS OR AS A FUNGICIDE, BACTERICIDE OR HERBICIDE FOR PLANTS

(54) Bezeichnung: VERWENDUNG VON PHOSPHORORGANISCHEN VERBINDUNGEN ZUR HERSTELLUNG VON ARZNEIMITTELN ZUR THERAPEUTISCHEN UND PROPHYLAKTISCHEN BEHANDLUNG VON INFESTIONEN ODER ALS FUNGIZID, BAKTERIZID ODER HERBIZID BEI PFLANZEN



(57) Abstract

The invention relates to the use of organophosphorous compounds of general formula (I) for producing medicaments for the therapeutic and prophylactic treatment of infections caused by viruses, bacteria, fungi and parasites, in humans and animals, and as a fungicide, bactericide and herbicide for plants.

(57) Zusammenfassung

Verwendung von phosphororganischen Verbindungen der allgemeinen Formel (I) zur Herstellung von Arzneimitteln zur therapeutischen und prophylaktischen Behandlung von Infektionen beim Mensch und Tier, verursacht durch Viren, Bakterien, Pilze und Parasiten und als Fungizid, Bakterizid und Herbizid bei Pflanzen.

Declaration and Power of Attorney for Patent Application

Erklärung für Patentanmeldungen mit Vollmacht

German Language Declaration

Als nachstehend benannter Erfinder erkläre ich hiermit an Eides Statt:

daß mein Wohnsitz, meine Postanschrift und meine Staatsangehörigkeit den im nachstehenden nach meinem Namen aufgeführten Angaben entsprechen, daß ich nach bestem Wissen der ursprüngliche, erste und alleinige Erfinder (falls nachstehend nur ein Name angegeben ist) oder ein ursprünglicher, erster und Miterfinder (falls nachstehend mehrere Namen aufgeführt sind) des Gegenstandes bin, für den dieser Antrag gestellt wird und für den ein Patent für die Erfindung mit folgendem Titel beantragt wird:

deren Beschreibung hier beigefügt ist, es sei denn (in diesem Falle Zutreffendes bitte ankreuzen), diese Erfindung

- ☐ wurde angemeldet am _____ unter der US-Anmeldenummer oder unter der Internationalen Anmeldenummer im Rahmen des Vertrags über die Zusammenarbeit auf dem Gebiet des Patentwesens (PCT) _____ und am _____ abgeändert (falls zutreffend).

Ich bestätige hiermit, daß ich den Inhalt der oben angegebenen Patentanmeldung, einschließlich der Ansprüche, die eventuell durch einen oben erwähnten Zusatzantrag abgeändert wurde, durchgesehen und verstanden habe.

Ich erkenne meine Pflicht zur Offenbarung jeglicher Informationen an, die zur Prüfung der Patentfähigkeit in Einklang mit Titel 37, Code of Federal Regulations, § 1.56 von Belang sind.

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled
USE OF ORGANOPHOSPHORUS COMPOUNDS FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS FOR THE THERAPEUTIC AND PROPHYLACTIC TREATMENT OF INFECTIONS
OR AS A FUNGICIDE, BACTERICIDE OR HERBICIDE IN PLANTS

the specification of which is attached hereto unless the following box is checked:

- ☒ was filed on September 22, 1999
as United States Application Number or PCT International Application Number
PCT/EP99/07054 and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56.

German Language Declaration

Ich beanspruche hiermit ausländische Prioritätsvorteile gemäß Title 35, US-Code, § 119 (a)-(d), bzw. § 365(b) aller unten aufgeführten Auslandsanmeldungen für Patente oder Erfinderurkunden, oder § 365(a) aller PCT internationalen Anmeldungen, welche wenigstens ein Land ausser den Vereinigten Staaten von Amerika benennen, und habe nachstehend durch ankreuzen sämtliche Auslandsanmeldungen für Patente bzw. Erfinderurkunden oder PCT internationale Anmeldungen angegeben, deren Anmeldetag dem der Anmeldung, für welche Priorität beansprucht wird, vorangeht.

Prior Foreign Applications
(Frühere ausländische Anmeldungen)

DE 198 43 222.4 German
(Number) (Country)
(Nummer) (Land)

(Number) (Country)
(Nummer) (Land)

Ich beanspruche hiermit Prioritätsvorteile unter Title 35, US-Code, § 119(e) aller US-Hilfsanmeldungen wie unten aufgezählt.

(Application No.) (Filing Date)
(Aktenzeichen) (Anmeldetag)

(Application No.) (Filing Date)
(Aktenzeichen) (Anmeldetag)

Ich beanspruche hiermit die mir unter Title 35, US-Code, § 120 zustehenden Vorteile aller unten aufgeführten US-Patentanmeldungen bzw. § 365(c) aller PCT internationalen Anmeldungen, welche die Vereinigten Staaten von Amerika benennen, und erkenne, insofern der Gegenstand eines jeden früheren Anspruchs dieser Patentanmeldung nicht in einer US-Patentanmeldung, bzw. PCT internationalen Anmeldung in einer gemäß dem ersten Absatz von Title 35, US-Code, § 112 vorgeschriebenen Art und Weise offenbart wurde, meine Pflicht zur Offenbarung jeglicher Informationen an, die zur Prüfung der Patentfähigkeit in Einklang mit Title 37, Code of Federal Regulations, § 1.56 von Belang sind und die im Zeitraum zwischen dem Anmeldetag der früheren Patentanmeldung und dem nationalen oder im Rahmen des Vertrags über die Zusammenarbeit auf dem Gebiet des Patentwesens (PCT) gültigen internationalen Anmeldetags bekannt geworden sind.

PCT/EP99/07054 September 22, 1999

(Application No.) (Filing Date)
(Aktenzeichen) (Anmeldetag)

(Application No.) (Filing Date)
(Aktenzeichen) (Anmeldetag)

Ich erkläre hiermit, daß alle in der vorliegenden Erklärung von mir gemachten Angaben nach bestem Wissen und Gewissen der Wahrheit entsprechen, und ferner daß ich diese eidesstattliche Erklärung in Kenntnis dessen abgebe, daß wissentlich und vorsätzlich falsche Angaben oder dergleichen gemäß § 1001, Title 18 des US-Code strafbar sind und mit Geldstrafe und/oder Gefängnis bestraft werden können und daß derartige wissentlich und vorsätzlich falsche Angaben die Rechtswirksamkeit der vorliegenden Patentanmeldung oder eines aufgrund deren erteilten Patentes gefährden können.

I hereby claim foreign priority under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Priority Not Claimed
Priorität nicht beansprucht

22 September 1998
(Day/Month/Year Filed)
(Tag/Monat/Jahr der Anmeldung)

☐

(Day/Month/Year Filed)
(Tag/Monat/Jahr der Anmeldung)

☐

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

Pending

(Status) (patented, pending, abandoned)
(Status) (patentiert, schwebend, aufgegeben)

(Status) (patented, pending, abandoned)
(Status) (patentiert, schwebend, aufgegeben)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

German Language Declaration

VERTRETUNGSVOLLMACHT: Als benannter Erfinder beauftrage ich hiermit den (die) nachstehend aufgeführten Patentanwalt (Patentanwältin) und/oder Vertreter mit der Verfolgung der vorliegenden Patentanmeldung sowie mit der Abwicklung aller damit verbundenen Angelegenheiten vor dem US-Patent- und Markenamt: (Name(n) und Registrierungsnummer(n) auflisten)

Postanschrift:

Telefonische Auskünfte: (Name und Telefonnummer)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: (list name and registration number)

Warren B. Kice Reg. No. 22,732; Jeffrey M. Becker, Reg. No. 35,442;

Howard Chen, Reg. no. 46,615; Randall E. Colson, Reg. No. 40,566;

9 Ruben C. DeLeon, Reg. No. 37,812; Brian Hubbard, Reg. No. 45,873;

David L. McCombs, Reg. No. 32,271; Bill Naifeh, Reg. No. 44,962;

Send Correspondence to: David M. O'Dell, Reg. No. 42,044

Warren B. Kice (214) 651-5634

Direct Telephone Calls to: (name and telephone number)

Haynes and Boone, LLP

901 Main Street, Suite 3100, Dallas TX 75202

Vor- und Zuname des einzigen oder ersten Erfinders	Full name of sole or first inventor Hassan Jomaa
Unterschrift des Erfinders Datum	Inventor's signature Date 3/9/01
Wohnsitz	Residence Breslauer Strasse 24, D-35398 Giessen, Germany
Staatsangehörigkeit	Citizenship German
Postanschrift	Post Office Address same as above
Vor- und Zuname des zweiten Miterfinders (falls zutreffend)	Full name of second joint inventor, if any
Unterschrift des zweiten Erfinders Datum	Second Inventor's signature Date
Wohnsitz	Residence
Staatsangehörigkeit	Citizenship
Postanschrift	Post Office Address

(Im Falle dritter und weiterer Miterfinder sind die entsprechenden Informationen und Unterschriften hinzuzufügen.)

(Supply similar information and signature for third and subsequent joint inventors.)